Takeda Pharmaceutical Co ADR (NYSE:TAK) shares, rose in value, with the stock price up by 1.04% to the previous day’s close as strong demand from buyers drove the stock to $13.62.
Actively observing the price movement in the last trading, the stock closed the session at $13.48. The value of beta (5-year monthly) was 0.54 whereas the PE ratio was 34.06 over 12-month period. Referring to stock’s 52-week performance, its high was $17.15, and the low was $13.19. On the whole, TAK has fluctuated by -7.28% over the past month.
The company’s Forward Dividend Ratio is 0.32, with its dividend yield at 2.34%.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that TAK’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 1702.93, with the price of TAK currently trading nearly -4.40% and -5.42% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.48, while the 7-day volatility ratio is showing 1.07% which for the 30-day chart, stands at 0.98%. Furthermore, Takeda Pharmaceutical Co ADR (TAK)’s beta value is 0.59, and its average true range (ATR) is 0.20.
A comparison of Takeda Pharmaceutical Co ADR (TAK) with its peers suggests the former has fared considerably weaker in the market. TAK showed an intraday change of 1.04% in last session, and over the past year, it shrunk by -18.30%%.
Data on historical trading for Takeda Pharmaceutical Co ADR (NYSE:TAK) indicates that the trading volumes over the past 10 days have averaged 1.71 million and over the past 3 months, they’ve averaged 1.85 million. According to company’s latest data on outstanding shares, there are 3.14 billion shares outstanding.
Nearly 0.02% of Takeda Pharmaceutical Co ADR’s shares belong to company insiders and institutional investors own 5.45% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.5 million shares as on Mar 15, 2024, resulting in a short ratio of 3.38. According to the data, the short interest in Takeda Pharmaceutical Co ADR (TAK) stood at 0.18% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 7.99 million. The stock has fallen by -4.56% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TAK stock heading into the next quarter.
